Cargando…

Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study

Pemafibrate, a novel selective peroxisome proliferator-activated receptor modulator, has beneficial effects on lipid metabolism. However, its effects on glucose metabolism in individuals with type 2 diabetes (T2DM) remain to be fully clarified. This was a subanalysis of the PARM-T2D study, a multice...

Descripción completa

Detalles Bibliográficos
Autores principales: Nomoto, Hiroshi, Kito, Kenichi, Iesaka, Hiroshi, Oe, Yuki, Kawata, Shinichiro, Tsuchida, Kazuhisa, Yanagiya, Shingo, Miya, Aika, Kameda, Hiraku, Cho, Kyu Yong, Sakuma, Ichiro, Manda, Naoki, Nakamura, Akinobu, Atsumi, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386707/
https://www.ncbi.nlm.nih.gov/pubmed/37514025
http://dx.doi.org/10.3390/pharmaceutics15071838
_version_ 1785081734208946176
author Nomoto, Hiroshi
Kito, Kenichi
Iesaka, Hiroshi
Oe, Yuki
Kawata, Shinichiro
Tsuchida, Kazuhisa
Yanagiya, Shingo
Miya, Aika
Kameda, Hiraku
Cho, Kyu Yong
Sakuma, Ichiro
Manda, Naoki
Nakamura, Akinobu
Atsumi, Tatsuya
author_facet Nomoto, Hiroshi
Kito, Kenichi
Iesaka, Hiroshi
Oe, Yuki
Kawata, Shinichiro
Tsuchida, Kazuhisa
Yanagiya, Shingo
Miya, Aika
Kameda, Hiraku
Cho, Kyu Yong
Sakuma, Ichiro
Manda, Naoki
Nakamura, Akinobu
Atsumi, Tatsuya
author_sort Nomoto, Hiroshi
collection PubMed
description Pemafibrate, a novel selective peroxisome proliferator-activated receptor modulator, has beneficial effects on lipid metabolism. However, its effects on glucose metabolism in individuals with type 2 diabetes (T2DM) remain to be fully clarified. This was a subanalysis of the PARM-T2D study, a multicenter prospective observational study on the use of pemafibrate versus conventional therapy for 52 weeks in subjects with T2DM complicated with hypertriglyceridemia. The subanalysis included participants who did not change their treatment for diabetes and did not receive insulin or insulin secretagogues during the study period. Changes in glucose metabolism markers, including homeostatic model assessment (HOMA2) scores and disposition index, were assessed. A total of 279 participants (141 in the pemafibrate group; 138 in the control group) met the criteria for the subanalysis. There were no significant changes in HbA1c during the 52-week study period in both groups. However, the pemafibrate group showed significant improvements versus the control group for insulin resistance assessed by HOMA2-R (−0.15 versus 0.08; estimated treatment difference −0.23 (95% confidence interval −0.44, −0.02); p = 0.03) and maintenance of β-cell function assessed by disposition index (0.015 versus −0.023; estimated treatment difference 0.037 (95% confidence interval 0.005, 0.069); p = 0.02). Correlation analyses showed that improvements in HOMA2-R and disposition index were significantly associated with improvements in lipid abnormalities and γ-glutamyl transpeptidase. In conclusion, pemafibrate reduced insulin resistance and maintained β-cell function in subjects with T2DM and hypertriglyceridemia, presumably by improving lipid profiles and lipid-related hepatocyte stress.
format Online
Article
Text
id pubmed-10386707
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103867072023-07-30 Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study Nomoto, Hiroshi Kito, Kenichi Iesaka, Hiroshi Oe, Yuki Kawata, Shinichiro Tsuchida, Kazuhisa Yanagiya, Shingo Miya, Aika Kameda, Hiraku Cho, Kyu Yong Sakuma, Ichiro Manda, Naoki Nakamura, Akinobu Atsumi, Tatsuya Pharmaceutics Article Pemafibrate, a novel selective peroxisome proliferator-activated receptor modulator, has beneficial effects on lipid metabolism. However, its effects on glucose metabolism in individuals with type 2 diabetes (T2DM) remain to be fully clarified. This was a subanalysis of the PARM-T2D study, a multicenter prospective observational study on the use of pemafibrate versus conventional therapy for 52 weeks in subjects with T2DM complicated with hypertriglyceridemia. The subanalysis included participants who did not change their treatment for diabetes and did not receive insulin or insulin secretagogues during the study period. Changes in glucose metabolism markers, including homeostatic model assessment (HOMA2) scores and disposition index, were assessed. A total of 279 participants (141 in the pemafibrate group; 138 in the control group) met the criteria for the subanalysis. There were no significant changes in HbA1c during the 52-week study period in both groups. However, the pemafibrate group showed significant improvements versus the control group for insulin resistance assessed by HOMA2-R (−0.15 versus 0.08; estimated treatment difference −0.23 (95% confidence interval −0.44, −0.02); p = 0.03) and maintenance of β-cell function assessed by disposition index (0.015 versus −0.023; estimated treatment difference 0.037 (95% confidence interval 0.005, 0.069); p = 0.02). Correlation analyses showed that improvements in HOMA2-R and disposition index were significantly associated with improvements in lipid abnormalities and γ-glutamyl transpeptidase. In conclusion, pemafibrate reduced insulin resistance and maintained β-cell function in subjects with T2DM and hypertriglyceridemia, presumably by improving lipid profiles and lipid-related hepatocyte stress. MDPI 2023-06-27 /pmc/articles/PMC10386707/ /pubmed/37514025 http://dx.doi.org/10.3390/pharmaceutics15071838 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nomoto, Hiroshi
Kito, Kenichi
Iesaka, Hiroshi
Oe, Yuki
Kawata, Shinichiro
Tsuchida, Kazuhisa
Yanagiya, Shingo
Miya, Aika
Kameda, Hiraku
Cho, Kyu Yong
Sakuma, Ichiro
Manda, Naoki
Nakamura, Akinobu
Atsumi, Tatsuya
Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study
title Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study
title_full Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study
title_fullStr Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study
title_full_unstemmed Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study
title_short Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study
title_sort favorable effect of pemafibrate on insulin resistance and β-cell function in subjects with type 2 diabetes and hypertriglyceridemia: a subanalysis of the parm-t2d study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386707/
https://www.ncbi.nlm.nih.gov/pubmed/37514025
http://dx.doi.org/10.3390/pharmaceutics15071838
work_keys_str_mv AT nomotohiroshi favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy
AT kitokenichi favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy
AT iesakahiroshi favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy
AT oeyuki favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy
AT kawatashinichiro favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy
AT tsuchidakazuhisa favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy
AT yanagiyashingo favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy
AT miyaaika favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy
AT kamedahiraku favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy
AT chokyuyong favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy
AT sakumaichiro favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy
AT mandanaoki favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy
AT nakamuraakinobu favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy
AT atsumitatsuya favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy